Janney Capital Upgrades Applied Genetic Technologies Corp to Neutral

Brokerage firm Janney Capital Upgrades its rating on Applied Genetic Technologies Corp(NASDAQ:AGTC). The shares have been rated Neutral. Previously, the analysts had a Sell rating on the shares. The rating by Janney Capital was issued on Sep 26, 2016.

In a different note, On Sep 13, 2016, Wells Fargo said it Downgrades its rating on Applied Genetic Technologies Corp. The shares have been rated ‘Market Perform’ by the firm. On Sep 13, 2016, Janney Capital said it Downgrades its rating on Applied Genetic Technologies Corp. The shares have been rated ‘Sell’ by the firm. On Sep 13, 2016, Cantor Fitzgerald said it Downgrades its rating on Applied Genetic Technologies Corp. The shares have been rated ‘Hold’ by the firm. On Sep 13, 2016, BMO Capital said it Maintains its rating on Applied Genetic Technologies Corp. In the research note, the firm Lowers the price-target to $25.00 per share. The shares have been rated ‘Outperform’ by the firm. On Sep 13, 2016, Roth Capital said it Downgrades its rating on Applied Genetic Technologies Corp. The shares have been rated ‘Neutral’ by the firm.

Applied Genetic Technologies Corp (AGTC) remained unchanged at the close of Thursday session. Even as the volume increased to 1,49,036 ,the shares failed to make any impression and ended at 0 points or 0.00% at $8.89. The trading session commenced at $9 and the stock hit a high of $9.05 and touched $8.75 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $21.43 and the 52-week low is $8.5. The company has a market cap of $160 M and has approximately 1,80,53,284 outstanding shares.

Applied Genetic Technologies Corp(AGTC) last announced its earnings results on Sep 12, 2016 for Fiscal Year 2016 and Q4.Company reported revenue of $12.11M. Analysts had an estimated revenue of $12.93M. Earnings per share were $0.15. Analysts had estimated an EPS of $0.07.

Several Insider Transactions has been reported to the SEC. On Sep 20, 2016, Lawrence E Bullock (CFO) purchased 10,000 shares at $8.75 per share price.Also, On Feb 12, 2015, Plc Glaxosmithkline (10% owner) sold 50,000 shares at $21.14 per share price.On Jan 26, 2015, Daniel L Menichella (V.P. & Chief Business Officer) sold 1,996 shares at $24.90 per share price, according to the Form-4 filing with the securities and exchange commission.

Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1) a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis an inherited condition causing early blindness. Its products also used to treat X-linked retinoschisis an inherited form of retinal degeneration affecting young males with poor vision either in infancy or at school age; and achromatopsia an inherited condition that is associated with color blindness visual acuity loss and extreme light sensitivity resulting in daytime blindness.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Applied Genetic Technologies Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Applied Genetic Technologies Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.